Top

Published in:

01-01-2012 | Original Article

Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists

Authors: L. A. Bradbury, S. Barlow, F. Geoghegan, R. A. Hannon, S. L. Stuckey, J. A. H. Wass, R. G. G. Russell, M. A. Brown, E. L. Duncan

Published in: Osteoporosis International | Issue 1/2012

Abstract

Summary

Bisphosphonates can increase bone mineral density (BMD) in children with osteogenesis imperfecta (OI). In this study of adults with OI type I, risedronate increased BMD at lumbar spine (but not total hip) and decreased bone turnover. However, the fracture rate in these patients remained high.

Introduction

Intravenous bisphosphonates given to children with OI can increase BMD and reduce fracture incidence. Oral and/or intravenous bisphosphonates may have similar effects in adults with OI. We completed an observational study of the effect of risedronate in adults with OI type I.

Methods

Thirty-two adults (mean age, 39 years) with OI type I were treated with risedronate (total dose, 35 mg weekly) for 24 months. Primary outcome measures were BMD changes at lumbar spine (LS) and total hip (TH). Secondary outcome measures were fracture incidence, bone pain, and change in bone turnover markers (serum procollagen type I aminopropeptide (P1NP) and bone ALP). A meta-analysis of published studies of oral bisphosphonates in adults and children with OI was performed.

Results

Twenty-seven participants (ten males and seventeen females) completed the study. BMD increased at LS by 3.9% (0.815 vs. 0.846 g/cm², p = 0.007; mean Z-score, −1.93 vs. −1.58, p = 0.002), with no significant change at TH. P1NP fell by 37% (p = 0.00041), with no significant change in bone ALP (p = 0.15). Bone pain did not change significantly (p = 0.6). Fracture incidence remained high, with 25 clinical fractures and 10 major fractures in fourteen participants (0.18 major fractures per person per year), with historical data of 0.12 fractures per person per year. The meta-analysis did not demonstrate a significant difference in fracture incidence in patients with OI treated with oral bisphosphonates.

Conclusions

Risedronate in adults with OI type I results in modest but significant increases in BMD at LS, and decreased bone turnover. However, this may be insufficient to make a clinically significant difference to fracture incidence.

Sykes B, Ogilvie D, Wordsworth P, Wallis G, Mathew C et al (1990) Consistent linkage of dominantly inherited osteogenesis imperfecta to the type I collagen loci: COL1A1 and COL1A2. Am J Hum Genet 46:293–307PubMed

Willing MC, Deschenes SP, Scott DA, Byers PH, Slayton RL et al (1994) Osteogenesis imperfecta type I: molecular heterogeneity for COL1A1 null alleles of type I collagen. Am J Hum Genet 55:638–647PubMed

Willing MC, Pruchno CJ, Atkinson M, Byers PH (1992) Osteogenesis imperfecta type I is commonly due to a COL1A1 null allele of type I collagen. Am J Hum Genet 51:508–515PubMed

Gajko-Galicka A (2002) Mutations in type I collagen genes resulting in osteogenesis imperfecta in humans. Acta Biochim Pol 49:433–441PubMed

Rauch F, Lalic L, Roughley P, Glorieux FH (2010) Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta. J Bone Miner Res 25:1367–1374PubMed

Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G et al (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947–952PubMedCrossRef

Rauch F, Plotkin H, Zeitlin L, Glorieux FH (2003) Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 18:610–614PubMedCrossRef

Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH (2003) Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 88:986–992PubMedCrossRef

Falk MJ, Heeger S, Lynch KA, DeCaro KR, Bohach D et al (2003) Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 111:573–578PubMedCrossRef

10.

Giraud F, Meunier PJ (2002) Effect of cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta. Open-label study in seven patients. Joint Bone Spine 69:486–490PubMedCrossRef

11.

Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE et al (2005) Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 20:977–986PubMedCrossRef

12.

Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M et al (2005) Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 20:758–763PubMedCrossRef

13.

DiMeglio LA, Peacock M (2006) Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res 21:132–140PubMedCrossRef

14.

Rauch F, Munns C, Land C, Cheung M, Glorieux F (2009) Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Miner Res 24(7):1282–1289PubMedCrossRef

15.

Ward LM, Rauch F, Whyte MP, D'Astous J, Gates PE et al (2011) Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab 96:355–364PubMedCrossRef

16.

Adami S, Gatti D, Colapietro F, Fracassi E, Braga V et al (2003) Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 18:126–130PubMedCrossRef

17.

Chevrel G, Schott AM, Fontanges E, Charrin JE, Lina-Granade G et al (2006) Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res 21:300–306PubMedCrossRef

18.

Pavon de Paz I, Iglesias Bolanos P, Duran Martinez M, Olivar Roldan J, Guijarro De Armas G et al (2010) Effects of zoledronic acid in adults with osteogenesis imperfecta. Endocrinol Nutr 57:245–250PubMedCrossRef

19.

Shapiro JR, McCarthy EF, Rossiter K, Ernest K, Gelman R et al (2003) The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta. Calcif Tissue Int 72:103–112PubMedCrossRef

20.

Lin HY, Lin SP, Chuang CK, Chen MR, Chang CY (2008) Intravenous pamidronate therapy in Taiwanese patients with osteogenesis imperfecta. Pediatr neonatol 49:161–165PubMedCrossRef

21.

Sanders KM, Nowson CA, Kotowicz MA, Briffa K, Devine A et al (2009) Calcium and bone health: position statement for the Australian and New Zealand Bone and Mineral Society, Osteoporosis Australia and the Endocrine Society of Australia. Med J Aust 190:316–320PubMed

22.

Shapiro JR, Thompson CB, Wu Y, Nunes M, Gillen C (2010) Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta. Calcif Tissue Int 87:120–129PubMedCrossRef

23.

Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M et al (2004) Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 363:1427–1431PubMedCrossRef

24.

Cohen J (1988) Statistical power analysis for the behavioural sciences. Lawrence Erlbaum Associates, Hillsdale

25.

Boonen S, Laan RF, Barton IP, Watts NB (2005) Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int 16:1291–1298PubMedCrossRef

26.

Paterson CR, McAllion S, Stellman JL (1984) Osteogenesis imperfecta after the menopause. N Engl J Med 310:1694–1696PubMedCrossRef

27.

Seikaly MG, Kopanati S, Salhab N, Waber P, Patterson D et al (2005) Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop 25:786–791PubMedCrossRef

28.

Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352PubMedCrossRef

29.

Bauer DC, Black DM, Garnero P, Hochberg M, Ott S et al (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19:1250–1258PubMedCrossRef

30.

Ruston D, Hoare J, Henderson L, Gregory J, Bates C et al (2004) The National Diet and Nutrition Survey: adults aged 19 to 64 years. In: Office for National Statistics MRCHNR at FSA (ed). Office of National Statistics, London

31.

Braga V, Gatti D, Rossini M, Colapietro F, Battaglia E et al (2004) Bone turnover markers in patients with osteogenesis imperfecta. Bone 34:1013–1016PubMedCrossRef

32.

Cundy T, Horne A, Bolland M, Gamble G, Davidson J (2007) Bone formation markers in adults with mild osteogenesis imperfecta. Clin Chem 53:1109–1114PubMedCrossRef

33.

Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J et al (2000) Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85:1846–1850PubMedCrossRef

34.

Vyskocil V, Pikner R, Kutilek S (2005) Effect of alendronate therapy in children with osteogenesis imperfecta. Joint Bone Spine 72:416–423PubMedCrossRef

35.

Bishop N, Harrison R, Ahmed F, Shaw N, Eastell R et al (2010) A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. J Bone Miner Res 25:32–40PubMedCrossRef

36.

Phillipi CA, Remmington T, Steiner RD (2008) Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev: CD005088

37.

Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759PubMedCrossRef

38.

Rauch F, Travers R, Plotkin H, Glorieux FH (2002) The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110:1293–1299PubMed

39.

Brown JJ, Zacharin MR (2009) Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis. J Pediatr Endocrinol Metab 22:55–63PubMedCrossRef

Title: Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists
Authors: L. A. Bradbury
S. Barlow
F. Geoghegan
R. A. Hannon
S. L. Stuckey
J. A. H. Wass
R. G. G. Russell
M. A. Brown
E. L. Duncan
Publication date: 01-01-2012
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 1/2012
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-011-1658-2

At a glance: The STEP trials

Springer Medicine

Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists

Abstract

Summary

Introduction

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors

Quantitative ultrasound of the heel and fracture risk assessment: an updated meta-analysis

Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis

GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates

Deletion of estrogen receptor beta accelerates early stage of bone healing in a mouse osteotomy model

Fracture risk assessment without bone density measurement in routine clinical practice